CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06564038
Title field or adapter rule: {'original_value': 'A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-11-01T01:03:12.983529+00:00
Published At: 2026-10-28T00:00:00+00:00
Record Updated At: 2026-10-28
Source Retrieved At: 2026-11-01T01:03:12.230707+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Chronic Lymphocytic Leukaemia", "Small Lymphocytic Lymphoma", "Mantle-cell Lymphoma", "Large B-cell Lymphoma", "B-cell Non-Hodgkin Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-28", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT06564038"
protocolSection.identificationModule.officialTitle: "A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['Substudy 1 (RR CLL/SLL): Cohort 1A (Surovatamig Monotherapy)', 'Substudy 1 (RR CLL/SLL): Cohort 1B (Surovatamig + Acalabrutinib)', 'Substudy 1 (RR CLL/SLL): Cohort 1C (Surovatamig Monotherapy)', 'Substudy 2 (RR MCL): Cohort 2A (Surovatamig Monotherapy)', 'Substudy 2 (RR MCL): Cohort 2C (Surovatamig Monotherapy)', 'Substudy 3 (LBCL): Cohort 3A 2SUD (Surovatamig + RCHOP)', 'Substudy 3 (LBCL): Cohort 3B 3SUD (Surovatamig + RCHOP)'], 'description': 'Surovatamig will be administered as either SC injection or IV infusion.', 'name': 'Surovatamig', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Substudy 3 (LBCL): Cohort 3A 2SUD (Surovatamig + RCHOP)', 'Substudy 3 (LBCL): Cohort 3B 3SUD (Surovatamig + RCHOP)'], 'description': 'Prednisone (or equivalent) will be administered either oral or IV infusion as per standard of care.', 'name': 'Prednisone (or equivalent)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Substudy 3 (LBCL): Cohort 3A 2SUD (Surovatamig + RCHOP)', 'Substudy 3 (LBCL): Cohort 3B 3SUD (Surovatamig + RCHOP)'], 'description': 'Rituximab will be administered as IV infusion as per standard of care.', 'name': 'Rituximab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Substudy 3 (LBCL): Cohort 3A 2SUD (Surovatamig + RCHOP)', 'Substudy 3 (LBCL): Cohort 3B 3SUD (Surovatamig + RCHOP)'], 'description': 'Cyclophosphamide will be administered as IV infusion as per standard of care.', 'name': 'Cyclophosphamide', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Substudy 3 (LBCL): Cohort 3A 2SUD (Surovatamig + RCHOP)', 'Substudy 3 (LBCL): Cohort 3B 3SUD (Surovatamig + RCHOP)'], 'description': 'Vincristine will be administered as IV infusion as per standard of care.', 'name': 'Vincristine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Substudy 3 (LBCL): Cohort 3A 2SUD (Surovatamig + RCHOP)', 'Substudy 3 (LBCL): Cohort 3B 3SUD (Surovatamig + RCHOP)'], 'description': 'Doxorubicin will be administered as IV infusion as per standard of care.', 'name': 'Doxorubicin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Substudy 1 (RR CLL/SLL): Cohort 1B (Surovatamig + Acalabrutinib)'], 'description': 'Acalabrutinib will be administered orally', 'name': 'Acalabrutinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.